ATAI vs. CMPS

In the year-to-date period, ATAI achieves a -15.60% return, which is significantly higher than CMPS's -54.63% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Atai Life Sciences N.V. (ATAI) and COMPASS Pathways plc (CMPS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ATAI Sharpe Ratio is -0.11, which is higher than the CMPS Sharpe Ratio of -0.66. The chart below compares the historical Sharpe Ratios of ATAI and CMPS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ATAI nor CMPS has paid dividends to shareholders.

The maximum ATAI drawdown since its inception was -94.77%, roughly equal to the maximum CMPS drawdown of -93.38%. Use the drawdown chart below to compare losses from any high point for ATAI and CMPS. For additional features, visit the drawdowns tool.

Atai Life Sciences N.V. (ATAI) and COMPASS Pathways plc (CMPS) have volatilities of 19.61% and 19.69%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Atai Life Sciences N.V. and COMPASS Pathways plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.